PE20050251A1 - Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc - Google Patents

Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc

Info

Publication number
PE20050251A1
PE20050251A1 PE2004000685A PE2004000685A PE20050251A1 PE 20050251 A1 PE20050251 A1 PE 20050251A1 PE 2004000685 A PE2004000685 A PE 2004000685A PE 2004000685 A PE2004000685 A PE 2004000685A PE 20050251 A1 PE20050251 A1 PE 20050251A1
Authority
PE
Peru
Prior art keywords
aliphatic
aryl
ns4a
protease
serine protease
Prior art date
Application number
PE2004000685A
Other languages
English (en)
Inventor
Robert B Perni
Shawn D Britt
Kevin M Cottrell
Janos Pitlik
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34079432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050251(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of PE20050251A1 publication Critical patent/PE20050251A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I DONDE X Y X' SON AMBOS FLUORINOS O CADA UNO ES C(H), N, NH, ENTRE OTROS; Y E Y' SON CADA UNO H, ARILO C6-C10, HETEROARILO C5-C10, ENTRE OTROS; R1 Y R3 SON CADA UNO CICLOALQUENILO, C1-C12-ALIFATICO, C6-C10-ARILO-C1-C12-ALIFATICO, ENTRE OTROS; R2, R4 Y R7 SON CADA UNO H, C1-C12-ALIFATICO, C6-C10-ARILO-C1-C12-ALIFATICO, ENTRE OTROS; R5 Y R5' SON CADA UNO H, C1-C12-ALIFATICO, ENTRE OTROS; V ES O, ENLACE DE VALENCIA; T ES C1-C12-ALIFATICO, C6-C10-ARILO, ENTRE OTROS; W ES (A), (B), ENTRE OTROS; DONDE R6 ES H, C6-C10-ARILO, C1-C12-ALIFATICO; ENTRE OTROS. TAMBIEN REFERIDA A LA PREPARACION DE ESTOS COMPUESTOS CUYOS PREFERIDOS SON: 3-ACETIL-4,5-DIMETIL-ACIDO CARBOXILICO PIRROL; 2-(2-{2-CICLOHEXIL-2-[(PIRAZINO-2-CARBONIL)-AMINO]-ACETILAMINO}-3,3-DIMETIL-BUTIRIL)-6.10-DITIA-2-AZAESPIRO[4,5]DECANO-3-ACIDO CARBOXILICO(1-CICLOPROPILAMINOOXALIL-BUTIL)-AMIDA; ENTRE OTROS. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE PROTEASA DE SERINA, DEL VIRUS DE HEPATITIS C DE LA PROTEASA NS3-NS4A, ENTRE OTRAS
PE2004000685A 2003-07-18 2004-07-16 Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc PE20050251A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48853503P 2003-07-18 2003-07-18

Publications (1)

Publication Number Publication Date
PE20050251A1 true PE20050251A1 (es) 2005-04-13

Family

ID=34079432

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000685A PE20050251A1 (es) 2003-07-18 2004-07-16 Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc

Country Status (19)

Country Link
US (2) US7109172B2 (es)
EP (3) EP2368900A3 (es)
JP (2) JP4745230B2 (es)
KR (2) KR20060052836A (es)
CN (3) CN1852920B (es)
AR (1) AR045916A1 (es)
AU (2) AU2004257288A1 (es)
BR (1) BRPI0412761A (es)
CA (1) CA2532664A1 (es)
HK (1) HK1098164A1 (es)
IL (2) IL173180A0 (es)
NO (1) NO20060706L (es)
NZ (1) NZ544789A (es)
PE (1) PE20050251A1 (es)
RU (1) RU2412198C2 (es)
TW (1) TW200523270A (es)
UY (1) UY28423A1 (es)
WO (1) WO2005007681A2 (es)
ZA (1) ZA200601420B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2314598A1 (en) * 1996-10-18 2011-04-27 Vertex Pharmaceuticals Incorporated Inhibitors of Hepatitis C virus NS3 serine protease
PT1268519E (pt) * 2000-04-03 2005-08-31 Vertex Pharma Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
NZ561851A (en) * 2002-04-11 2009-05-31 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
CN1852920B (zh) * 2003-07-18 2010-12-15 沃泰克斯药物股份有限公司 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
PE20050374A1 (es) * 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
WO2005028502A1 (en) 2003-09-18 2005-03-31 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
NZ546663A (en) * 2003-10-10 2010-01-29 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7365092B2 (en) * 2003-10-10 2008-04-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CA2543696A1 (en) * 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
JP2008505849A (ja) * 2004-02-04 2008-02-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特に、ｈｃｖ、ｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
EA016071B1 (ru) 2005-05-13 2012-01-30 Вирокем Фарма Инк. Соединения и способы лечения или предотвращения флавивирусных инфекций
CA2611155A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Pharmaceutical formulations and methods of treatment using the same
NZ563361A (en) 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
WO2007016589A2 (en) * 2005-08-02 2007-02-08 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CA2629343A1 (en) 2005-11-11 2007-05-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP2340836A1 (en) 2006-02-27 2011-07-06 Vertex Pharmceuticals Incorporated Co-crystals comprising VX-950 and their pharmaceutical compositions
BRPI0709567A2 (pt) 2006-03-16 2011-07-12 Vertex Pharma inibidores deuterados de protease de hepatite c
MX2008013119A (es) 2006-04-11 2008-10-21 Novartis Ag Inhibidores de hcv/vih y sus usos.
DK2041156T3 (en) 2006-07-13 2014-02-24 Achillion Pharmaceuticals Inc 4-AMINO-4-OXOBUTANOYL Peptides AS INHIBITORS OF VIRUS REPLICATION
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
WO2008057995A2 (en) * 2006-11-02 2008-05-15 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
AU2007321677B2 (en) 2006-11-15 2013-04-11 Vertex Pharmaceuticals (Canada) Incorporated Thiophene analogues for the treatment or prevention of flavivirus infections
WO2008086053A1 (en) * 2007-01-03 2008-07-17 Virobay, Inc. Hcv inhibitors
GEP20125645B (en) 2007-02-27 2012-09-25 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
AU2008219704A1 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
CA2696053A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
CN101835774B (zh) 2007-08-30 2014-09-17 弗特克斯药品有限公司 共晶体和包含该共晶体的药物组合物
KR101762842B1 (ko) 2008-12-10 2017-08-04 아칠리온 파르마세우티칼스 인코포레이티드 바이러스 복제 억제제로서 유용한 신규한 4-아미노-4-옥소부타노일 펩티드
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
ES2588204T3 (es) 2009-09-15 2016-10-31 Taigen Biotechnology Co., Ltd. Inhibidores de la proteasa de HCV
AU2010326225A1 (en) 2009-11-25 2012-06-07 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
AU2010336355A1 (en) 2009-12-24 2012-07-05 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
AU2011232348A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
EP2550268A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119853A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119858A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
JP2013531011A (ja) 2010-06-28 2013-08-01 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
JP2013529684A (ja) 2010-06-28 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AU2011292040A1 (en) 2010-08-17 2013-03-07 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flaviviridae viral infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2013016501A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Formulations of thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
US20130123276A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
SG11201507469RA (en) 2013-03-14 2015-10-29 Achillion Pharmaceuticals Inc Processes for producing sovaprevir
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
MX2015013020A (es) 2013-03-15 2016-06-10 Achillion Pharmaceuticals Inc Polimorfos de sovaprevir y metodos de fabricacion de los mismos.
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
JP6737781B2 (ja) * 2014-10-27 2020-08-12 インヒブルクス，インコーポレイティド セルピン融合ポリペプチド及びその使用方法
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
UA124672C2 (uk) 2016-06-21 2021-10-27 Оріон Офтальмолоджі Ллс Гетероциклічні похідні пролінаміду
CN113167802A (zh) 2018-12-04 2021-07-23 百时美施贵宝公司 通过多同位素体反应监测使用样品内校准曲线的分析方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
EP2314598A1 (en) 1996-10-18 2011-04-27 Vertex Pharmaceuticals Incorporated Inhibitors of Hepatitis C virus NS3 serine protease
DK0966465T3 (da) 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
DE69934104T2 (de) 1998-03-31 2007-06-28 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von hepatitis c virus ns3 protease
CZ301802B6 (cs) 1999-03-19 2010-06-30 Vertex Pharmaceuticals Incorporated Deriváty mocoviny jako inhibitory IMPDH a farmaceutické prostredky s jejich obsahem
PT1268519E (pt) * 2000-04-03 2005-08-31 Vertex Pharma Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
ES2279879T3 (es) 2001-07-11 2007-09-01 Vertex Pharmaceuticals Incorporated Inhibidores biciclicos puente de la serina proteasa.
CA2462163A1 (en) * 2001-10-24 2003-05-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
NZ561851A (en) * 2002-04-11 2009-05-31 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
EP1545706A1 (en) 2002-09-04 2005-06-29 Quantum Devices, Inc. Optoelectronic device for the treatment of muscle or joint pain
CN100453553C (zh) * 2003-04-11 2009-01-21 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
CN1852920B (zh) 2003-07-18 2010-12-15 沃泰克斯药物股份有限公司 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
PE20050374A1 (es) * 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
WO2005028502A1 (en) 2003-09-18 2005-03-31 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7365092B2 (en) * 2003-10-10 2008-04-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
NZ546663A (en) * 2003-10-10 2010-01-29 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP2008505849A (ja) * 2004-02-04 2008-02-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特に、ｈｃｖ、ｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
AU2008219704A1 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases

Also Published As

Publication number Publication date
NZ544789A (en) 2010-01-29
JP2011116784A (ja) 2011-06-16
ZA200601420B (en) 2007-06-27
CN101724022A (zh) 2010-06-09
AU2004257288A1 (en) 2005-01-27
AU2010257200B2 (en) 2011-10-20
EP2341065A2 (en) 2011-07-06
IL218698A0 (en) 2012-05-31
JP2008500265A (ja) 2008-01-10
RU2412198C2 (ru) 2011-02-20
US7109172B2 (en) 2006-09-19
UY28423A1 (es) 2005-02-28
AR045916A1 (es) 2005-11-16
AU2004257288A2 (en) 2008-06-26
HK1098164A1 (en) 2007-07-13
KR20120013450A (ko) 2012-02-14
WO2005007681A2 (en) 2005-01-27
CA2532664A1 (en) 2005-01-27
AU2010257200A1 (en) 2011-01-13
KR20060052836A (ko) 2006-05-19
IL173180A0 (en) 2006-06-11
RU2006105002A (ru) 2006-08-27
CN102020700A (zh) 2011-04-20
TW200523270A (en) 2005-07-16
EP1646642A2 (en) 2006-04-19
WO2005007681A3 (en) 2005-06-02
CN1852920B (zh) 2010-12-15
US20050107304A1 (en) 2005-05-19
CN1852920A (zh) 2006-10-25
BRPI0412761A (pt) 2006-09-26
JP4745230B2 (ja) 2011-08-10
US20060211629A1 (en) 2006-09-21
EP2341065A3 (en) 2012-06-20
EP2368900A3 (en) 2012-07-04
EP2368900A2 (en) 2011-09-28
NO20060706L (no) 2006-02-14
US8691758B2 (en) 2014-04-08

Similar Documents

Publication Publication Date Title
PE20050251A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc
PE20050374A1 (es) Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
CY1107200T1 (el) Ενωσεις αναστολης της ηπατιτιδας c
PE20080457A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasas de hepatitis c
ATE539744T1 (de) Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
ATE349463T1 (de) Verbrückte bizyklische serinproteaseinhibitoren
PE20080539A1 (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
BRPI0407827A (pt) compostos de aminoeteroarila como inibidores de proteìna cinase
PE20030857A1 (es) Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
ATE512971T1 (de) Peptidanaloga als hepatitis c-hemmer
MA30198B1 (fr) Inhibiteurs de la protease ns3 du vhc
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
HK1101402A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
MA29757B1 (fr) Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
PE20080072A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
EA199800661A1 (ru) Ингибиторы аспартильных протеаз
HUP0402081A2 (hu) NK-2 antagonista hatású egyenes láncú bázisos vegyületek és ezeket tartalmazó gyógyszerészeti készítmények
WO2002074777A3 (en) Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity
PE20081312A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
TH78149B (th) แมโครไซคลิกเปปไทด์ที่ออกฤทธิ์ต่อต้านไวรัสตับอักเสบชนิด c
TH124102B (th) สารยับยั้งเปปไทโดไมเมทิค โพรทีเอส

Legal Events

Date Code Title Description
FC Refusal